Webinar: Affordable Off-the-Shelf CAR γδT Cells via CRISPR/AAV
Join our webinar about making cell therapy more affordable and accessible. Dr. Meisam Naeimi will walk you through the importance of off-the-shelf CAR-T cells in making therapies more affordable and accessible, the development of CRISPR/AAV-based off-the-shelf CAR γδT cells and preclinical efficiacy.
Online
Making Cell Therapy Affordable and Accessible: Off-the-Shelf CAR γδT Cells Generated Using CRISPR/AAV
Join our webinar about making cell therapy more affordable and accessible. Dr. Meisam Naeimi will walk you through the importance of off-the-shelf CAR-T cells in making therapies more affordable and accessible, the development of CRISPR/AAV-based off-the-shelf CAR γδT cells and preclinical efficiacy.
Register here Learn more about MedChem Express (MCE)
In This Webinar, You Will Learn
The importance of off-the-shelf CAR-T cells in making therapies more affordable and accessible Next-generation engineering: the development of CRISPR/AAV-based off-the-shelf CAR γδT cells to overcome the limitations of traditional CAR-T therapies Preclinical efficacy: the potent antitumor activity of CAR γδT cells demonstrated across multiple tumor types
About this Webinar
Cell therapy has transformed cancer treatment but remains costly and inaccessible for many patients. Using a novel γδT cell and CRISPR/AAV platform, we have developed off-the-shelf CAR γδT cells that combine strong antitumor activity with global scalability. I will share recent data on the CD38-CAR for hematological malignancies, as well as the GD2- and Nucleolin-CAR γδT cells. This work paves the way for affordable and accessible cell therapies worldwide.
Speaker
Meisam Naeimi, PhD - Principal Investigator, Nationwide Children’s Hospital·The Ohio State University
Dr. Meisam Naeimi’s mission is to bring cellular therapies to low- and middle-income countries. At Nationwide Children’s Hospital and The Ohio State University, he leads a translational research program focused on gene-edited T and γδT cell therapies for high-grade gliomas, T-ALL, and other hard-to-treat malignancies. He currently serves as Chief Scientific Officer at CARTx Therapeutics, where he drives the development of next-generation allogeneic CAR γδT cell therapies for both pediatric and adult cancers.
Dr. Naeimi has pioneered CRISPR/AAV-based engineering platforms to generate potent off-the-shelf CAR γδT cells, including CD38-, GD2-, and Nucleolin-directed constructs, and has advanced multiple collaborations to scale these therapies globally. His work bridges academic innovation with industry translation, supported by a strong track record in preclinical development, grant funding, and strategic partnerships.
Related images
